Veracyte is a genomic diagnostics company. Co.'s products include the following: Afirma Genomic Sequencing Classifier and Xpression Atlas, which includes the Afirma GSC and Xpression Atlas; Percepta Bronchial Genomic Classifier, which improves lung cancer diagnosis by improving the performance of diagnostic bronchoscopies; Envisia Genomic Classifier, which improves diagnosis of idiopathic pulmonary fibrosis; and Prosigna Breast Cancer Prognostic Gene Signature Assay, which uses genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The VCYT stock yearly return is shown above.
The yearly return on the VCYT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VCYT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|